Chemical structure of molecule SAR439859

oral sel. estrogen receptor degrader (SERD)

400 mg QD, in Ph. II for ER+/HER2- BC

from MTS of ER binders, opt. for degrd./antag.

Mol. Cancer Ther., Dec. 11, 2020

Sanofi, Vitry-sur-Seine, FR / Cambridge MA

Sanofi oral selective estrogen receptor (ER) degrader (SERD)


 this content is exclusive to
Premium members

Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.